Lola Rodríguez-Ruiz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lola Rodríguez-Ruiz has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Diana García-Moreno
Instituto Murciano de Investigación Biosanitaria (IMIB-Pascual Parrilla), Spain
3 shared publications - Juan M. Lozano-Gil
Departamento de Biología Celular e Histología, Facultad de Biología, Universidad de Murcia, Murcia, Spain
3 shared publications - Maria Luisa Cayuela
Grupo de Telomerasa, Cáncer y Envejecimiento, Hospital Clínico Universitario Virgen de la Arrixaca, 30120 Murcia, Spain
3 shared publications - Sylwia D. Tyrkalska
Instituto Murciano de Investigación Biosanitaria (IMIB-Pascual Parrilla), Murcia, Spain
3 shared publications - Victoriano Mulero
Departamento de Biología Celular e Histología, Facultad de Biología, Universidad de Murcia, Spain
3 shared publications - Alicia Martínez-López
Instituto Murciano de Investigación Biosanitaria (IMIB-Pascual Parrilla), Murcia, Spain
2 shared publications
Latest Publications
- Open Access
- 21 July 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 8904
Ninjurins regulate hematopoietic stem cell amplification through canonical WNT signaling independent of plasma membrane rupture
- 21 July 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 8904
Open AccessNinjurins regulate hematopoietic stem cell amplification through canonical WNT signaling independent of plasma membrane rupture
- Open Access
- 9 January 2026
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 18 (2) , 702-724
TKI-mediated inhibition of NLRP1 inflammasome restores erythropoiesis in DBA syndrome
Diamond-Blackfan anemia syndrome (DBAS) is marked by defective erythropoiesis caused by impaired ribosome biogenesis and aberrant signaling. Here, we investigate how ribosomal stress-induced activation of the NLRP1 inflammasome affects erythroid differentiation in DBAS. We demonstrate that FDA/EMA-approved tyrosine kinase inhibitors (TKIs) effectively mitigate defective erythropoiesis by inhibiting NLRP1 inflammasome activation. In K562 cells, nilotinib suppresses the ZAKα/P38/NLRP1/CASP1 axis, leading to increased GATA1 levels and upregulation of key erythroid genes. These effects were validated in human CD34⁺ hematopoietic stem and progenitor cells (HSPCs) and zebrafish models, where nilotinib, imatinib, and dasatinib promoted erythropoiesis while reducing caspase-1 activity. In Rps19-deficient zebrafish, RPS19-deficient human HSPCs, and HSPCs from DBAS patients, TKIs rescued erythroid differentiation and restored hemoglobin levels. Our findings highlight that targeting the NLRP1 inflammasome with TKIs may provide a novel therapeutic strategy for DBAS and other ribosomopathies.
- 9 January 2026
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 18 (2) , 702-724
Open AccessTKI-mediated inhibition of NLRP1 inflammasome restores erythropoiesis in DBA syndrome
Diamond-Blackfan anemia syndrome (DBAS) is marked by defective erythropoiesis caused by impaired ribosome biogenesis and aberrant signaling. Here, we investigate how ribosomal stress-induced activation of the NLRP1 inflammasome affects erythroid differentiation in DBAS. We demonstrate that FDA/EMA-approved tyrosine kinase inhibitors (TKIs) effectively mitigate defective erythropoiesis by inhibiting NLRP1 inflammasome activation. In K562 cells, nilotinib suppresses the ZAKα/P38/NLRP1/CASP1 axis, leading to increased GATA1 levels and upregulation of key erythroid genes. These effects were validated in human CD34⁺ hematopoietic stem and progenitor cells (HSPCs) and zebrafish models, where nilotinib, imatinib, and dasatinib promoted erythropoiesis while reducing caspase-1 activity. In Rps19-deficient zebrafish, RPS19-deficient human HSPCs, and HSPCs from DBAS patients, TKIs rescued erythroid differentiation and restored hemoglobin levels. Our findings highlight that targeting the NLRP1 inflammasome with TKIs may provide a novel therapeutic strategy for DBAS and other ribosomopathies.
- Open Access
- 7 September 2023
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 15 (10) , e18142
ZAKα/P38 kinase signaling pathway regulates hematopoiesis by activating the NLRP1 inflammasome
Chronic inflammatory diseases are associated with hematopoietic lineage bias, including neutrophilia and anemia. We have recently identified that the canonical inflammasome mediates the cleavage of the master erythroid transcription factor GATA1 in hematopoietic stem and progenitor cells (HSPCs). We report here that genetic inhibition of Nlrp1 resulted in reduced number of neutrophils and increased erythrocyte counts in zebrafish larvae. We also found that the NLRP1 inflammasome in human cells was inhibited by LRRFIP1 and FLII, independently of DPP9, and both inhibitors regulated hematopoiesis. Mechanistically, erythroid differentiation resulted in ribosomal stress‐induced activation of the ZAKα/P38 kinase axis which, in turn, phosphorylated and promoted the assembly of NLRP1 in both zebrafish and human. Finally, inhibition of Zaka with the FDA/EMA‐approved drug Nilotinib alleviated neutrophilia in a zebrafish model of neutrophilic inflammation and promoted erythroid differentiation and GATA1 accumulation in K562 cells. In conclusion, our results reveal that the NLRP1 inflammasome regulates hematopoiesis and pave the way to develop novel therapeutic strategies for the treatment of hematopoietic alterations associated with chronic inflammatory and rare diseases.
- 7 September 2023
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 15 (10) , e18142
Open AccessZAKα/P38 kinase signaling pathway regulates hematopoiesis by activating the NLRP1 inflammasome
Chronic inflammatory diseases are associated with hematopoietic lineage bias, including neutrophilia and anemia. We have recently identified that the canonical inflammasome mediates the cleavage of the master erythroid transcription factor GATA1 in hematopoietic stem and progenitor cells (HSPCs). We report here that genetic inhibition of Nlrp1 resulted in reduced number of neutrophils and increased erythrocyte counts in zebrafish larvae. We also found that the NLRP1 inflammasome in human cells was inhibited by LRRFIP1 and FLII, independently of DPP9, and both inhibitors regulated hematopoiesis. Mechanistically, erythroid differentiation resulted in ribosomal stress‐induced activation of the ZAKα/P38 kinase axis which, in turn, phosphorylated and promoted the assembly of NLRP1 in both zebrafish and human. Finally, inhibition of Zaka with the FDA/EMA‐approved drug Nilotinib alleviated neutrophilia in a zebrafish model of neutrophilic inflammation and promoted erythroid differentiation and GATA1 accumulation in K562 cells. In conclusion, our results reveal that the NLRP1 inflammasome regulates hematopoiesis and pave the way to develop novel therapeutic strategies for the treatment of hematopoietic alterations associated with chronic inflammatory and rare diseases.